Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis

Pediatric PulmonologyVolume 58, Issue 5 p. 1592-1594 LETTER Elexacaftor/tezacaftor/ivacaftor treatment reduces airway inflammation in cystic fibrosis Richard C. De Vuyst MD, Corresponding Author Richard C. De Vuyst MD [email protected] orcid.org/0000-0002-1561-8546 Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Correspondence Richard C. De Vuyst, MD, Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Email: [email protected] Contribution: Writing - original draft, Data curation, ​InvestigationSearch for more papers by this authorErin Bennard RN, Erin Bennard RN Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: ​Investigation, Data curationSearch for more papers by this authorCharissa W. Kam PharmD, Charissa W. Kam PharmD orcid.org/0000-0003-3419-2613 Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA Contribution: Data curation, Writing - review & editingSearch for more papers by this authorCameron J. McKinzie PharmD, Cameron J. McKinzie PharmD orcid.org/0000-0003-1401-5628 Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA Contribution: Data curation, Writing - review & editingSearch for more papers by this authorCharles R. Esther MD, PhD, Charles R. Esther MD, PhD orcid.org/0000-0002-8081-2986 Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Supervision, Writing - review & editing, Conceptualization, Methodology, Formal analysisSearch for more papers by this author Richard C. De Vuyst MD, Corresponding Author Richard C. De Vuyst MD [email protected] orcid.org/0000-0002-1561-8546 Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Correspondence Richard C. De Vuyst, MD, Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Email: [email protected] Contribution: Writing - original draft, Data curation, ​InvestigationSearch for more papers by this authorErin Bennard RN, Erin Bennard RN Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: ​Investigation, Data curationSearch for more papers by this authorCharissa W. Kam PharmD, Charissa W. Kam PharmD orcid.org/0000-0003-3419-2613 Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA Contribution: Data curation, Writing - review & editingSearch for more papers by this authorCameron J. McKinzie PharmD, Cameron J. McKinzie PharmD orcid.org/0000-0003-1401-5628 Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, North Carolina, USA Contribution: Data curation, Writing - review & editingSearch for more papers by this authorCharles R. Esther MD, PhD, Charles R. Esther MD, PhD orcid.org/0000-0002-8081-2986 Department of Pediatrics, Division of Pediatric Pulmonology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Contribution: Supervision, Writing - review & editing, Conceptualization, Methodology, Formal analysisSearch for more papers by this author First published: 31 January 2023 https://doi.org/10.1002/ppul.26334Citations: 1Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. REFERENCES 1Ghigo A, Prono G, Riccardi E, De Rose V. Dysfunctional inflammation in cystic fibrosis airways: from mechanisms to novel therapeutic approaches. Int J Mol Sci. 2021; 22(4):1952. doi:10.3390/ijms22041952 2Roesch EA, Nichols DP, Chmiel JF. Inflammation in cystic fibrosis: an update. Pediatr Pulmonol. 2018; 53(June): S30-S50. doi:10.1002/ppul.24129 3Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med. 2014; 190(2): 175-184. doi:10.1164/rccm.201404-0703OC 4McNally P, Butler D, Karpievitch YV, et al. Ivacaftor and airway inflammation in preschool children with cystic fibrosis. Am J Respir Crit Care Med. 2021; 204(5): 605-608. 5Veltman M, De Sanctis JB, Stolarczyk M, et al. CFTR correctors and antioxidants partially normalize lipid imbalance but not abnormal basal inflammatory cytokine profile in CF bronchial epithelial cells. Front Physiol. 2021; 12(February):619442. doi:10.3389/fphys.2021.619442 6Nichols DP, Paynter AC, Heltshe SL, et al. Clinical effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: a clinical trial. Am J Respir Crit Care Med. 2022; 205(5): 529-539. doi:10.1164/rccm.202108-1986oc Citing Literature Volume58, Issue5May 2023Pages 1592-1594 ReferencesRelatedInformation